Apyx Medical Corp (NASDAQ: APYX) closed the day trading at $1.32 down -28.65% from the previous closing price of $1.85. In other words, the price has decreased by -$0.5300 from its previous closing price. On the day, 1242780 shares were traded. APYX stock price reached its highest trading level at $1.5500 during the session, while it also had its lowest trading level at $1.2895.
Ratios:
For a better understanding of APYX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.74 and its Current Ratio is at 5.52. In the meantime, Its Debt-to-Equity ratio is 1.44 whereas as Long-Term Debt/Eq ratio is at 1.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on July 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $8.
On May 20, 2022, Lake Street started tracking the stock assigning a Buy rating and target price of $12.
Dougherty & Company reiterated its Buy rating for the stock on April 02, 2019, while the target price for the stock was revised from $12 to $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 12 ’23 when HILL MATTHEW C bought 2,500 shares for $2.19 per share. The transaction valued at 5,475 led to the insider holds 2,500 shares of the business.
Goodwin Charles D. II bought 50,000 shares of APYX for $78,500 on Nov 14 ’23. The Chief Executive Officer now owns 90,000 shares after completing the transaction at $1.57 per share. On Jun 26 ’23, another insider, Hornsby Todd, who serves as the Executive Vice President of the company, sold 15,000 shares for $7.56 each. As a result, the insider received 113,400 and left with 40 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APYX now has a Market Capitalization of 46.08M and an Enterprise Value of 38.33M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.87 while its Price-to-Book (P/B) ratio in mrq is 1.71. Its current Enterprise Value per Revenue stands at 0.76 whereas that against EBITDA is -2.46.
Stock Price History:
Over the past 52 weeks, APYX has reached a high of $7.97, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is 2.1535, while the 200-Day Moving Average is calculated to be 3.4750.
Shares Statistics:
Over the past 3-months, APYX traded about 96.07K shares per day on average, while over the past 10 days, APYX traded about 190.42k shares per day. A total of 34.64M shares are outstanding, with a floating share count of 30.16M. Insiders hold about 12.93% of the company’s shares, while institutions hold 49.49% stake in the company. Shares short for APYX as of Feb 29, 2024 were 1.59M with a Short Ratio of 16.53, compared to 1.51M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.58% and a Short% of Float of 4.76%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.18 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.23, while EPS last year was -$0.17. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.1 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.37 and -$0.5 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.52, with 5 analysts recommending between -$0.45 and -$0.59.
Revenue Estimates
5 analysts predict $14.85M in revenue for the current quarter. It ranges from a high estimate of $15.87M to a low estimate of $14.2M. As of the current estimate, Apyx Medical Corp’s year-ago sales were $12.61M, an estimated increase of 17.80% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $13.73M, an increase of 13.10% less than the figure of $17.80% in the same quarter last year. There is a high estimate of $14.49M for the next quarter, whereas the lowest estimate is $12.6M.
A total of 5 analysts have provided revenue estimates for APYX’s current fiscal year. The highest revenue estimate was $53.55M, while the lowest revenue estimate was $51.9M, resulting in an average revenue estimate of $52.52M. In the same quarter a year ago, actual revenue was $44.51M, up 18.00% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $59.76M in the next fiscal year. The high estimate is $63.45M and the low estimate is $56.9M. The average revenue growth estimate for next year is up 13.80% from the average revenue estimate for this year.
